Literature DB >> 26535042

Highlight report: Role of the circadian clock system in breast cancer.

Ahmed Ghallab1.   

Abstract

Entities:  

Year:  2015        PMID: 26535042      PMCID: PMC4614034          DOI: 10.17179/excli2015-269

Source DB:  PubMed          Journal:  EXCLI J        ISSN: 1611-2156            Impact factor:   4.068


× No keyword cloud information.

‬‬‬

It is well known that the circadian clock system coordinates physiological functions throughout the day (Dibner et al., 2010[5]; Mohawk et al., 2012[12]; Fu and Lee, 2003[6]; Hammad et al., 2013[9]). Circadian rhythms are generated by molecular feedback loops; transcriptional activators induce the expression of genes that repress their own transcription (Lowrey and Takahashi, 2011[11]). Disruption of circadian rhythms has been discussed as a possible risk factor of cancer. For example, epidemiological studies have suggested that working at night increases the risk of breast cancer (Kamdar et al., 2013[10]). However, recently a comprehensive study including 766 breast cancer patients has been published that broadens our understanding of the role of the circadian clock system in breast cancer (Cadenas et al., 2014[3]). The authors studied all known clock genes in relation to prognosis. Interestingly, loss of expression of circadian clock genes in tumour tissue was associated with a clearly higher risk to develop metastasis (Cadenas et al., 2014[3]). Recently, numerous studies have been performed to identify prognostic genes in breast cancer (e.g. Sicking et al., 2014[18][17]; Siggelkow et al., 2012[19]; Godoy et al., 2014[8]; Schmidt et al., 2008[13][14]; Cadenas, 2012;[1] Cadenas et al., 2010[2]; Ghallab, 2014[7]). However, loss of circadian clock genes seems to be of independent prognostic influence. The association of decreased circadian clock gene expression was also observed in different molecular subtypes of breast cancer (Desmedt et al., 2007[4]; Schmidt et al., 2008[13][14], 2009[16]) and was independent of established clinical factors. But the perhaps most interesting result of Cadenas et al. (2014[3]) was obtained by pairwise analysis of functionally related clock genes. PER3 and CRY2 are proteins that form dimers acting as negative feedback regulators and are known to show similar oscillation patterns. Therefore, a strong correlation between both genes can be anticipated. Indeed the authors observed strong correlations between CRY2 and PER3 in well-differentiated tumours that did not grow aggressively (Cadenas et al., 2014[3]). In contrast, the correlation between both clock genes was lost in more aggressive carcinomas. This breakdown of correlation between clock genes was also observed with loss of expression of the estrogen receptor, amplification of the oncogene HER2 and increasing histological grade (Cadenas et al., 2014[3]). In conclusion, Cadenas and colleagues have clearly shown that loss of clock gene expression and particularly the breakdown of coordinated co-expression of clock genes is associated with worse prognosis and dedifferentiation, a feature so far unknown in breast cancer.
  17 in total

1.  Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series.

Authors:  Christine Desmedt; Fanny Piette; Sherene Loi; Yixin Wang; Françoise Lallemand; Benjamin Haibe-Kains; Giuseppe Viale; Mauro Delorenzi; Yi Zhang; Mahasti Saghatchian d'Assignies; Jonas Bergh; Rosette Lidereau; Paul Ellis; Adrian L Harris; Jan G M Klijn; John A Foekens; Fatima Cardoso; Martine J Piccart; Marc Buyse; Christos Sotiriou
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

2.  Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer.

Authors:  Cristina Cadenas; Dennis Franckenstein; Marcus Schmidt; Mathias Gehrmann; Matthias Hermes; Bettina Geppert; Wiebke Schormann; Lindsey J Maccoux; Markus Schug; Anika Schumann; Christian Wilhelm; Evgenia Freis; Katja Ickstadt; Jörg Rahnenführer; Jörg I Baumbach; Albert Sickmann; Jan G Hengstler
Journal:  Breast Cancer Res       Date:  2010-06-28       Impact factor: 6.466

Review 3.  The circadian clock: pacemaker and tumour suppressor.

Authors:  Loning Fu; Cheng Chi Lee
Journal:  Nat Rev Cancer       Date:  2003-05       Impact factor: 60.716

4.  Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response.

Authors:  Patricio Godoy; Cristina Cadenas; Birte Hellwig; Rosemarie Marchan; Joanna Stewart; Raymond Reif; Miriam Lohr; Matthias Gehrmann; Jörg Rahnenführer; Markus Schmidt; Jan G Hengstler
Journal:  Breast Cancer       Date:  2012-09-22       Impact factor: 4.239

5.  The humoral immune system has a key prognostic impact in node-negative breast cancer.

Authors:  Marcus Schmidt; Daniel Böhm; Christian von Törne; Eric Steiner; Alexander Puhl; Henryk Pilch; Hans-Anton Lehr; Jan G Hengstler; Heinz Kölbl; Mathias Gehrmann
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

Review 6.  Night-shift work and risk of breast cancer: a systematic review and meta-analysis.

Authors:  Biren B Kamdar; Ana I Tergas; Farrah J Mateen; Neil H Bhayani; Jiwon Oh
Journal:  Breast Cancer Res Treat       Date:  2013-02-12       Impact factor: 4.872

7.  Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients.

Authors:  Isabel Sicking; Karlien Rommens; Marco J Battista; Daniel Böhm; Susanne Gebhard; Antje Lebrecht; Cristina Cotarelo; Gerald Hoffmann; Jan G Hengstler; Marcus Schmidt
Journal:  BMC Cancer       Date:  2014-12-15       Impact factor: 4.430

8.  Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients.

Authors:  Isabel Sicking; Karolina Edlund; Eva Wesbuer; Veronika Weyer; Marco J Battista; Antje Lebrecht; Christine Solbach; Marianna Grinberg; Johannes Lotz; Gerald Hoffmann; Jörg Rahnenführer; Jan G Hengstler; Marcus Schmidt
Journal:  PLoS One       Date:  2014-10-23       Impact factor: 3.240

9.  Highlights in tumor metabolome research: Choline metabolism influences integrin expression and supports cell attachment.

Authors:  Ahmed Ghallab
Journal:  EXCLI J       Date:  2014-08-19       Impact factor: 4.068

10.  Loss of circadian clock gene expression is associated with tumor progression in breast cancer.

Authors:  Cristina Cadenas; Leonie van de Sandt; Karolina Edlund; Miriam Lohr; Birte Hellwig; Rosemarie Marchan; Marcus Schmidt; Jörg Rahnenführer; Henrik Oster; Jan G Hengstler
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

View more
  4 in total

1.  Highlight report: Predicting late metastasis in breast cancer.

Authors:  Seddik Hammad; Gada S Osman; Mohamed Ezzeldien; Hassan Ahmed; Ahmed M Kotb
Journal:  EXCLI J       Date:  2016-12-23       Impact factor: 4.068

2.  Highlight report: Limits of prognostication of non-small cell lung cancer.

Authors:  Alshaimaa Adawy
Journal:  EXCLI J       Date:  2017-05-31       Impact factor: 4.068

3.  Highlight report: Intratumoral metabolomic heterogeneity of breast cancer.

Authors:  Regina Stoeber
Journal:  EXCLI J       Date:  2017-12-22       Impact factor: 4.068

4.  Highlight report: The relationship of DNA copy number alterations and mRNA levels in cancer.

Authors:  Seddik Hammad
Journal:  EXCLI J       Date:  2017-12-21       Impact factor: 4.068

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.